Sernova Biotherapeutics

About Sernova Biotherapeutics

Sernova Biotherapeutics is focused on developing regenerative solutions for chronic diseases, particularly Type 1 Diabetes (T1D). Their mission is to restore the body's normal function using their unique Cell Pouch™ bio-hybrid organ and therapeutic cell technology, enabling patients to live their lives fully by addressing the underlying causes of chronic conditions.

Products & Services

Cell Pouch™ Bio-Hybrid Organ:A bio-hybrid organ designed to restore normal body function for patients with Type 1 Diabetes and other chronic diseases through regenerative therapeutic cell technology.

Comprehensive Therapies for Chronic Diseases:Developing therapies for various indications where patients lack necessary hormones, factors, and proteins due to chronic conditions.

Specialties

Regenerative Medicine Type 1 Diabetes Treatment Bio-Hybrid Organ Technology Therapeutic Cell Technology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 4000000 MR: - FA: CAD$4,000,000 FAN: 4000000	D: 2025-04-17 FD: 2025-04-17	1 investors
2	RT: Convertible Debt T: - FT: Convertible Debt	A: 1000000 MR: - FA: CAD$1,000,000 FAN: 1000000	D: 2025-03-05 FD: 2025-03-05	1 investors
3	RT: Marketed Public Offering of Units T: - FT: Marketed Public Offering of Units	A: 6500000 MR: - FA: $6,500,000 to $10,000,000 FAN: 6500000	D: 2024-06-06 FD: 2024-06-06	7 investors

Debt Latest

2025-04-17

$4.0M

1 investor (Pro only)

Convertible Debt 2025-03-05

$1.0M

Marketed Public Offering of Units 2024-06-06

$6.5M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jonathan Rigby

Interim Chair and Chief Executive Officer

LinkedIn (Pro only)

J

James Parsons

Chief Financial Officer

LinkedIn (Pro only)

M

Marylyn Rigby

Chief Communications Officer

LinkedIn (Pro only)

P

Pericles (Perry) Calias, PhD

Chief Development Officer and Head of R&D

D

David Burke

Vice President, Investor Relations

M

Marie Kaldchibachi, CPA, CA

Director, Finance

View 22 more team members with Pro

Unlock Full Team Directory

Recent News